BCOP 2019 Self-Study Online Module Release I
BCOP Self-Study Online Modules - both releases will cover topics from all the BCOP domains and multiple hematology/oncology patient populations, and feature recent articles from primary oncology literature. BCOP Self-Study Modules are on-demand and allow you to review at your convenience.
Each module will include access to articles, pre-assessment questions, patient cases and the BCOP posttest. You may choose to complete all or select individual modules, receiving BCOP credit for each completed module which achieves a passing score.
Case study questions will count towards the overall test score for the BCOP credit. Your results in the case studies and the posttest questions will determine your total score which still must meet the 75% threshold for passing to earn BCOP credit.
Your purchase of Self-Study Release I includes 4 modules and offers up to 7.5 BCOP/ACPE credits.
Module 1: Updates in Breast Cancer (1.0 BCOP/ACPE)
Module 2: Hepatitis B (2.0 BCOP/ACPE)
Module 3: Radiation Oncology (2.5 BCOP/ACPE)
Module 4: Complementary and Alternative Medicine and Mindfulness (2.0 BCOP/ACPE)
HOPA Member Price: $165
Non-Member Price: $225
2019 BCOP Self-Study Online Module – Release I is also a part of both the 2019 BCOP Program Bundle and BCOP Self-Study Online Module Bundle. If you’ve already purchased the 2019 BCOP Program Bundle or BCOP Self-Study Online Module Bundle, you can access your Self-Study Modules in My Education Library .
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by February 23, 2022.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form, case-study and post-test, with a combined passing grade of 75% or greater is achieved. Tests must be completed by August 28, 2019.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict: Planners and Managers Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.
Module 1: Updates in Breast Cancer
Description: The purpose of this module is to review pertinent updates in breast cancer treatment focusing on both early stage and metastatic disease. Disease state background information is provided as well as three clinical trials in breast cancer. These trials include TAILORx which reviews changes to interpretation of Oncotype Dx recurrence scores, as well as ExteNET and MONARCH3 which review clinical trial data from two newer breast cancer oral chemotherapy medications.Learning Objectives
- Summarize the results of TAILORx study and apply the results to patients
- Explain the rationale for and key clinical points associated with use of neratinib as extended adjuvant therapy in HER2-positive breast cancer
- Explain the rationale for and key clinical points associated with use of abemaciclib as initial therapy in advanced HR-positive, HER2-negative breast cancer
Speaker: Alison Palumbo, PharmD, MPH, BCOP; Clay Cuny, PharmD
Disclosure: Clay Cuny - No financial relationships exist with commercial interests. Alison Palumbo – Oregon Society of Health Systems Pharmacists Fall Seminar – SP – H, Hematology Oncology Pharmacist Association Practice Management – SP –H, NCI PDQ Supportive and Palliative Care Editorial Board – A – H, Oncology Reimbursement Management – A – H
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hours (.10 CEUs) under the ACPE universal activity number 0465-0000-19-050-H04-P.
Activity Type: Application
Module 2: Hepatitis B
Description:Hepatitis B reactivation can be a concerning complication of high risk patients receiving chemotherapy and immunosuppressive agents. The Hepatitis B self-study module will review current recommendations for screening patients to decrease this risk. This module will also address identifiying serological results for hepatitis B and explore prophylaxis and treatment strategies. The clinical trial examining the efficacy of different antiviral agents for prophylaxis will also be reviewed.
- Analyze current recommendations for the screening, prophylaxis and treatment of Hepatitis B for high risk patients
- Identify high risk patients that should be screened and interpret the serological results for Hepatitis B
- Compare the efficacy of entecavir and lamuvidine in preventing Hepatitis B reactivation in high risk patients
Speaker: Syeda Saba Kareem PharmD BCOP, Lauren Campanella, PharmD BCOP
Disclosure: Lauren Campanella - No financial relationships exist with commercial interests. Syeda Saba Kareem - No financial relationships exist with commercial interests.
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 2.0 contact hours (.20 CEUs) under the ACPE universal activity number 0465-0000-19-051-H04-P.
Activity Type: Application
Module 3: Radiation Oncology
Description: Radiation therapy is widely utilized throughout the cancer care continuum, in combination with other therapies, and in early, advanced or metastatic disease. Technological advances in radiation oncology continue to optimize outcomes for patients and minimize harm. This self-study module aims to provide an overview for the oncology pharmacists on the advances that have improved management, the role of combination radio-immunotherapy, and the future-direction of radiotherapy. Additionally, this module highlights two landmark trials that have led to the approval of Tumor-Targeting Fields in glioblastoma multiforme and 177Lu-Dotatate in the treatment of midgut neuroendocrine tumors. Upon completion, the audience should have a better understanding of radiotherapy, monitoring of patients undergoing treatment, counseling, side effect management and when to make therapeutic interventions.
- Review recent advances in radiation oncology in the treatment of cancer
- Discuss the role of combination radiotherapy and immunotherapy in the management of cancer
- Compare the outcomes of temozolomide with and without Tumor-Treating Fields in the treatment of glioblastoma
- Understand the role of 177Lu-Dotatate in the treatment of midgut neuroendocrine tumors
Speaker: Kirollos S. Hanna, PharmD, BCPS, BCOP
Disclosures: Amgen – A, C – H, Takeda – A, C – H, Heron – A, C – H, Hyloris – A, C – H
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 2.5 contact hours (.25 CEUs) under the ACPE universal activity number 0465-0000-19-052-H04-P.
Activity Type: Application
Module 4: Complementary and Alternative Medicine and Mindfulness
Description: Complementary and alternative medicine (CAM) therapy is becoming more prevalent in cancer care. There are a number of concerns related to patients undergoing cancer treatment, including drug interactions with herbals and supplements and physical restrictions with surgery and radiation. The pharmacist should be aware of these issues as well as an overall understanding of the evidence behind any CAM therapies so that they can best advise the patient and providers. This module includes one set of guidelines for CAM therapies as well as a review article on acupuncture’s role in cancer pain management.
- Examine consensus guidelines regarding management of cancer- and treatment-related toxicities with complementary and integrative therapies.
- Compare complementary and integrative therapies, considering the literature to support it as well as the potential advantages and disadvantages for patients.
- Recommend certain complementary and integrative therapies based on a patient’s medical wants or needs.
Speaker: Christy Harris, PharmD BCPS BCOP
Disclosures: No financial relationships exist with commercial interests.
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 2.0 contact hours (.20 CEUs) under the ACPE universal activity number 0465-0000-053-H04-P.
Activity Type: Application